Maria Lowe, Pharm.D., BCPS, associate vice president of pharmaceutical intelligence at the Institute for Clinical and ...
Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...
Zacks Investment Research on MSN11h
Roche's Higher Dose of Ocrevus Fails to Meet Goal in RMS StudySwiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus ...
Clinical Trials Arena on MSN14h
Roche’s high-dose Ocrevus fails primary endpoint in MS trialHigher doses of the company’s intravenously delivered multiple sclerosis drug failed to show additional benefit in slowing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback